Animal Models & Preclinical In Vivo Services

Boveevo supports preclinical drug development through a broad range of in vivo disease models and pharmacology studies, selected around the mechanism of action, therapeutic area, and development stage of each program. Our expertise spans oncology, immunology, metabolic disease, cardiovascular, fibrosis, neuroscience, and infectious disease models, enabling evaluation of efficacy, pharmacology, safety, and translational biomarkers in relevant biological systems.

Our oncology capabilities include CDX, PDX, syngeneic, orthotopic, metastatic, humanized, and immuno-oncology models, while our metabolic and inflammatory portfolio includes diet-induced obesity, db/db and ob/ob diabetes, MASH/NAFLD, inflammation, and autoimmune models. We also support cardiovascular, fibrosis, Parkinson’s, Alzheimer’s, and infectious-disease research using established and fit-for-purpose animal models.

These models can be integrated with pharmacology and efficacy studies, PK/PD, dose-range finding, tolerability, clinical pathology, histopathology, IHC/IF, ex vivo tissue biomarker analysis, and biodistribution or molecular endpoint assessment. This integrated approach connects in vivo efficacy with pharmacodynamic and translational evidence, helping generate a more complete understanding of therapeutic response and dose–exposure relationships.

For programs requiring specialized species or non-human primate studies, we coordinate qualified partner capabilities to extend study scope while maintaining appropriate scientific and operational oversight.

In Vivo Services

Oncology
✔️ CDX, PDX, Syngeneic and Orthotopic Tumour Models
✔️ Metastatic Tumour Models
✔️ Humanized Mouse Models
✔️ Immuno-Oncology Models

Inflammation & Autoimmune Disease
✔️ Inflammation Models
✔️ Autoimmune Disease Models
✔️ Ex Vivo Tissue Biomarker Analysis
✔️ Histopathology, IHC & IF

Metabolic Health
✔️ Diet-Induced Obesity (DIO) Models
✔️ db/db and ob/ob Diabetes Models
✔️ MASH / NAFLD Models
✔️ Metabolic Pharmacology & Efficacy Studies

Cardiovascular Disease
✔️ Cardiovascular Disease Models
✔️ Pharmacology & Efficacy Studies
✔️ PK/PD Assessment
✔️ Clinical Pathology & Tissue Biomarkers

Fibrosis
✔️ Fibrosis Disease Models
✔️ Pharmacology & Efficacy Studies
✔️ Histopathology, IHC & IF
✔️ Molecular & Tissue Biomarker Assessment

Neuroscience
✔️ Parkinson’s Disease Models
✔️ Alzheimer’s Disease Models
✔️ Neuropharmacology & Efficacy Studies
✔️ Molecular and Histopathological Endpoints

Infectious Diseases
✔️ Infectious-Disease Models
✔️ Therapeutic Efficacy Studies
✔️ PK/PD Assessment
✔️ Tissue and Molecular Endpoint Analysis

Pharmacology & Translational Assessment
✔️ Pharmacology & Efficacy Studies
✔️ PK / PD Studies
✔️ Dose-Range Finding
✔️ Tolerability Studies
✔️ Clinical Pathology
✔️ Histopathology / IHC / IF
✔️ Ex Vivo Tissue Biomarkers
✔️ Biodistribution / Molecular Endpoints
✔️ Specialized Species / NHP Studies through Qualified Partners